Lakewood-Amedex Biotherapeutics Inc. is facing a significant challenge as it risks being delisted from the Nasdaq Stock Market due to its common stock price falling below the required minimum. The company received a notification from Nasdaq on November 10, 2026, indicating that its stock had been below $1.00 per share for 30 consecutive business days, violating the Bid Price Rule.

This potential delisting is crucial not only for Lakewood-Amedex but also for the broader pharmaceutical preparations industry, which includes companies that may face similar challenges in maintaining compliance with stock exchange requirements.

Company Background

Lakewood-Amedex Biotherapeutics Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol LABT. Lakewood-Amedex is recognized as an emerging growth company and is incorporated in Nevada. Its principal office is located in University Park, Florida.

What the Filing Says

According to the recent SEC filing, Lakewood-Amedex received a letter from Nasdaq stating, "for the 30 consecutive business days from September 29, 2026, through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share." The letter further explains that due to a previous reverse stock split on June 22, 2026, the company is not eligible for a compliance period under Nasdaq rules.

The filing notes that unless the company requests a hearing by November 17, 2026, trading of its common stock will be suspended on November 19, 2026. Nasdaq will then file a Form 25-NSE to remove the company’s securities from listing and registration.

Impact

This situation may affect a variety of stakeholders, including investors, employees, and the broader market. A delisting could diminish investor confidence in Lakewood-Amedex and similar emerging growth companies within the pharmaceutical sector. The company plans to request a hearing to present its case and a plan to regain compliance, which may include another reverse stock split.

What’s Next

The company intends to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay the suspension of its securities and the filing of the Form 25-NSE pending the Panel's decision. The outcome of this hearing is uncertain, and there is no guarantee that the Panel will allow Lakewood-Amedex to continue its listing on Nasdaq.